These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 19114364)

  • 81. [Short-term substitution of calcineurin inhibitors (CNI) with recombinant humanized anti-CD25 monoclonal antibody (Basiliximab) as aGVHD prophylaxis in CNI intolerant patients after allogeneic hematopoietic stem cell transplantation].
    Shao S; Liu HX; Jiang Y; Li S; Wei DL; Zhu J; Wang C; Zhao CX
    Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):115-120. PubMed ID: 38604786
    [No Abstract]   [Full Text] [Related]  

  • 82. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease.
    MacMillan ML; Weisdorf DJ; Davies SM; DeFor TE; Burns LJ; Ramsay NK; Wagner JE; Blazar BR
    Biol Blood Marrow Transplant; 2002; 8(1):40-6. PubMed ID: 11858189
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
    Srinivasan R; Chakrabarti S; Walsh T; Igarashi T; Takahashi Y; Kleiner D; Donohue T; Shalabi R; Carvallo C; Barrett AJ; Geller N; Childs R
    Br J Haematol; 2004 Mar; 124(6):777-86. PubMed ID: 15009066
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Antithymocyte globulin used for treatment of severe acute graft versus host disease after haploidentical bone marrow transplantation].
    Liu J; Wang HX; Duan LN; Xue M; Zhu L; Yang HM; Ding L; Ji SQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):816-8. PubMed ID: 17708810
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants.
    Bacigalupo A; Lamparelli T; Milone G; Sormani MP; Ciceri F; Peccatori J; Locasciulli A; Majolino I; Di Bartolomeo P; Mazza F; Sacchi N; Pollicheni S; Pinto V; Van Lint MT;
    Bone Marrow Transplant; 2010 Feb; 45(2):385-91. PubMed ID: 19584823
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Microparticles for diagnosis of graft-versus-host disease after allogeneic stem transplantation.
    Rank A; Nieuwland R; Toth B; Pihusch V; Delker R; Hiller E; Kolb HJ; Pihusch R
    Transplantation; 2011 Jul; 92(2):244-50. PubMed ID: 21629178
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.
    Gao Z; Fan Z; Liu Z; Ye X; Zeng Y; Xuan L; Huang F; Lin R; Sun J; Liu Q; Xu N
    Front Immunol; 2024; 15():1408211. PubMed ID: 39021571
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation.
    Wang JZ; Liu KY; Xu LP; Liu DH; Han W; Chen H; Chen YH; Zhang XH; Zhao T; Wang Y; Huang XJ
    Transplant Proc; 2011 Jun; 43(5):1928-33. PubMed ID: 21693302
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.
    Kim SS
    Ann Pharmacother; 2007 Sep; 41(9):1436-44. PubMed ID: 17684033
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.
    Schroeder T; Haas R; Kobbe G
    Expert Rev Hematol; 2010 Oct; 3(5):633-51. PubMed ID: 21083479
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Comparison study on treatment of acute graft-versus-host disease with low-dose methotrexate in combination with low-dose methylprednisolone or standard-dose methylprednisolone].
    Wang J; Xu LP; Liu DH; Liu KY; Chen H; Chen YH; Han W; Wang Y; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):512-5. PubMed ID: 22338171
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The response-guided ATG treatment provides a survival benefit and KPS recovery for patients with steroid refractory acute GVHD: The Nagasaki Transplant Group Experience.
    Fujioka M; Itonaga H; Furumoto T; Kasai S; Sakamoto H; Kitanosono H; Kato T; Horai M; Sato S; Sawayama Y; Taguchi J; Imaizumi Y; Hata T; Yoshida S; Moriuchi Y; Miyazaki Y
    Transpl Immunol; 2021 Aug; 67():101417. PubMed ID: 34058354
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia.
    Lv M; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X; Mo X
    Front Med; 2019 Dec; 13(6):667-679. PubMed ID: 31512033
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
    Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
    Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [The role of CD25 antibody in unrelated hematopoietic stem cell transplantation].
    Hu LD; Chen H; Jiang M; Li BT; Yu ZY; Li YH
    Zhonghua Nei Ke Za Zhi; 2005 Nov; 44(11):848-50. PubMed ID: 16316569
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Extracorporeal photopheresis: a useful therapy for patients with steroid-refractory acute graft-versus-host disease but not for the prevention of the chronic form.
    Rubegni P; Feci L; Poggiali S; Marotta G; D'Ascenzo G; Murdaca F; Fimiani M
    Br J Dermatol; 2013 Aug; 169(2):450-7. PubMed ID: 23534380
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
    Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
    Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Prophylaxis and treatment of chronic graft versus host disease].
    Huang K; Li Y; Huang SL; Fang JP; Zhou DH; Chen C
    Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):174-7. PubMed ID: 15833186
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Membranous nephropathy with nephrotic syndrome developed after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia].
    Aimoto M; Yamane T; Ichii M; Mori K; Moriguchi-Aimoto R; Wada-Inoue E; Koh H; Nakane T; Takeoka Y; Akahori-Nakamae M; Nishiki-Kosaka S; Terada Y; Nakamae H; Koh KR; Nakao T; Ohsawa M; Wakasa K; Ishimura E; Inaba M; Hino M
    Rinsho Ketsueki; 2011 Jul; 52(7):556-62. PubMed ID: 21821990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.